Lubiprostone for Chronic Idiopathic Constipation Treatment
Status:
Completed
Trial end date:
2017-06-05
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of oral administration of 24
ug of lubiprostone twice daily (BID) for 4 weeks in participants with chronic idiopathic
constipation (CIC) compared with placebo.